{
    "code": 0,
    "data": [
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio recording of earnings conference call Q3 FY25-26",
            "news_id": "54c040da-6b61-4435-8049-a0df072e8d26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ec2824b7-a917-4b22-a59a-66dfc9532dd8.pdf",
            "news_date": "2026-02-12 18:07:55",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio recording of earnings conference call Q3 FY25-26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ec2824b7-a917-4b22-a59a-66dfc9532dd8.pdf",
            "news_date": "2026-02-12 18:07:55"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Outcome",
            "descriptor": "Dividend",
            "caption": "Corporate Action-Board approves Dividend",
            "news_body": "Board of Directors at their meeting held today declared 3rd Interim Dividend of Rs.1.50 per equity share of Rs.2/- each",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7d14c90b-e418-4f7a-9951-0a2e217efe05.pdf",
            "news_date": "2026-02-12 16:00:53"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Meeting Updates",
            "caption": "Announcement under Regulation 30 (LODR)-Meeting Updates",
            "news_body": "The Board of Directors at their meeting held today approved to incorporate a wholly owned subsidiary in CHILE",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=75d16543-ab42-436f-8c6d-4814ccf5ba6d.pdf",
            "news_date": "2026-02-12 15:58:35"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Management",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
            "news_body": "1. Superannuation of Mr. S V V N Appa Rao Chief Financial Officer  w.e.f. closure of business hours on 12th February 2026\r\n2. Appointment of Mr. Amit Parekh as Chief Financial Officer of the Company w.e.f. 13th February 2026.\r\n3. Appointment of Mr. K Srinivasa Rao as Executive Vice President- Pharma Division w.e.f. 12th February 2026",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=64ca9579-8416-499d-b919-357bb4dd7dac.pdf",
            "news_date": "2026-02-12 15:54:03"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation on Q3 earning  for FY 2025-26",
            "news_id": "df996c37-b072-4210-be86-8306658d4c08",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=236bc8c2-778b-4af2-a104-b4e902651e29.pdf",
            "news_date": "2026-02-12 15:04:56",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation on Q3 earning  for FY 2025-26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=236bc8c2-778b-4af2-a104-b4e902651e29.pdf",
            "news_date": "2026-02-12 15:04:56"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un Audited Financial Results For The Quarter Ending 31St December 2025",
            "news_body": "Un audited Financial Results for the quarter ending 31st December 2025",
            "news_id": "7da53498-9d53-4372-9921-2373d20a2392",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a4f3defc-e429-4997-ab79-1a096fb5d689.pdf",
            "news_date": "2026-02-12 14:49:23",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Un Audited Financial Results For The Quarter Ending 31St December 2025",
            "news_body": "Un audited Financial Results for the quarter ending 31st December 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a4f3defc-e429-4997-ab79-1a096fb5d689.pdf",
            "news_date": "2026-02-12 14:49:23"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Out Come Of Board Meeting",
            "news_body": "outcome of the board meeting",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dd6a96ab-e75e-483d-8fe0-bea4b0ce8b24.pdf",
            "news_date": "2026-02-12 14:35:51"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Natco Receives Tentative Approval for Erdafitinib Tables (generic of Balversa) from the United States Food and Drug Administration (U.S.FDA)",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e548f346-7e78-4b57-9617-1b5967f62377.pdf",
            "news_date": "2026-02-03 14:54:54"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "NATCO receives Tentative Approval for Erdafitinib Tablets (generic of Balversa)",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1b666a2c-80ce-468d-9117-0ee6f576b1de.pdf",
            "news_date": "2026-02-03 13:17:02"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of Q3FY26 Un-audited Financial Results Earnings Call",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=344754bd-bc80-48e9-9cab-2283ddd8fe1b.pdf",
            "news_date": "2026-02-02 16:08:09"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=284b10cf-0027-44c2-a3d5-9f6d74a12639.pdf",
            "news_date": "2026-01-30 12:47:09"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Considering The Unaudited Financial Results For The Quarter And  Period Ended 31St December 2025 And Declaration Of 3Rd Interim Dividend If Any For FY 2025-26",
            "news_body": "Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 inter alia to consider and approve the unaudited Financial Results for the quarter and  period ended 31st December 2025 and declaration of 3rd Interim Dividend if any for FY 2025-26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=832fa727-a931-46a7-bc6d-2b101a0a4dd5.pdf",
            "news_date": "2026-01-28 15:47:10"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Clarification",
            "news_body": "Clarification",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bcc49d23-9bbb-4ee3-ad56-6e7b9f04c4fc.pdf",
            "news_date": "2026-01-07 11:54:26"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General",
            "descriptor": "Clarification",
            "caption": "Clarification sought from Natco Pharma Ltd",
            "news_body": "The Exchange has sought clarification from Natco Pharma Ltd on January 7 2026 with reference to news appeared in https://economictimes.indiatimes.com/ dated January 7 2026 quoting \"HC seeks Novo Nordisks reply on Natco plea to revoke patent\"<BR><BR>The reply is awaited.",
            "file_url": "",
            "news_date": "2026-01-07 11:04:48"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f36a5074-f4a1-4a78-9874-abf18a76eab9.pdf",
            "news_date": "2026-01-06 16:32:55"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Sustainability Report For The Year 2024-25",
            "news_body": "Sustainability Report for the year 2024-25",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=33803185-1672-4114-942f-f9e9105f6a7b.pdf",
            "news_date": "2026-01-05 17:05:26"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Closure of Trading Window w.e.f. January 1 2026",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bf9aaeb7-e893-4222-acb2-40a3699b4763.pdf",
            "news_date": "2025-12-29 12:08:40"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Management",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
            "news_body": "Appointment of Mr. Amit Parekh as Executive Vice President - Finance & Accounts w.e.f. 2nd December 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3c4fe6f3-ad2f-4ced-a74a-ccde568f1571.pdf",
            "news_date": "2025-12-02 12:34:47"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Credit Rating",
            "caption": "Announcement under Regulation 30 (LODR)-Credit Rating",
            "news_body": "Intimation of Credit Rating",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=db3708a8-1a6a-419f-9963-34cf310b0f8a.pdf",
            "news_date": "2025-11-29 09:49:45"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Conclusion of USFDA inspection at our Manali Chennai API unit",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9b2d41a9-3420-409f-bc37-c2eb702cfe47.pdf",
            "news_date": "2025-11-21 16:12:27"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings call Transcript for the quarter and half year ended September 30 2025 held on November 14 2025",
            "news_id": "a1e4e501-6c2c-4aaf-8440-3d7c4bc73b60",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac8f848f-8703-4403-9ae3-cb2d420d47da.pdf",
            "news_date": "2025-11-20 16:39:44",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings call Transcript for the quarter and half year ended September 30 2025 held on November 14 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac8f848f-8703-4403-9ae3-cb2d420d47da.pdf",
            "news_date": "2025-11-20 16:39:44"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Newspaper Publication",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bc60f214-6b86-4929-8317-7a7fde2d4879.pdf",
            "news_date": "2025-11-15 11:54:18"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Q2 FY 2025-26 earning call audio transcript",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=07a576ac-c4ac-4dda-9416-135464ec2290.pdf",
            "news_date": "2025-11-15 11:50:54"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation on the Financial Results for the quarter and half year ended 30th September 2025",
            "news_id": "31221785-ea0e-495d-9078-174f8daee992",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c5fe60cd-6aa5-4ff4-9fd3-1e93a3014e6e.pdf",
            "news_date": "2025-11-14 15:07:43",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation on the Financial Results for the quarter and half year ended 30th September 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c5fe60cd-6aa5-4ff4-9fd3-1e93a3014e6e.pdf",
            "news_date": "2025-11-14 15:07:43"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Outcome",
            "descriptor": "Dividend",
            "caption": "Corporate Action-Board approves Dividend",
            "news_body": "The Board of Directors approved the 2nd Interim Dividend of Rs.1.50 (75%) per Equity Share of Rs.2/- each for the FY 2025-26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=96915a2c-0661-47a6-bfc0-f9483c435465.pdf",
            "news_date": "2025-11-14 13:46:23"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For The Quarter And Half Year Ended 30Th September 2025",
            "news_body": "Outcome of the Board Meeting",
            "news_id": "ffb45051-a929-448a-90ae-0ec960958725",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a28a0f3b-934c-4399-ab82-f394a1e15065.pdf",
            "news_date": "2025-11-14 13:44:12",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Financial Results For The Quarter And Half Year Ended 30Th September 2025",
            "news_body": "Outcome of the Board Meeting",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a28a0f3b-934c-4399-ab82-f394a1e15065.pdf",
            "news_date": "2025-11-14 13:44:12"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Intimation",
            "descriptor": "Record Date",
            "caption": "Record Date For Payment Of 2Nd Interim Dividend For The FY 2025-26",
            "news_body": "Record Date for payment of 2nd Interim Dividend for the FY 2025-26 is 20th November 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e95031fe-04ac-4e24-8804-579d89bf3de4.pdf",
            "news_date": "2025-11-14 13:36:59"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "Outcome of Board Meeting held on 14th November 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=96ac9946-02d7-4d10-b551-a542bbdb1075.pdf",
            "news_date": "2025-11-14 13:31:08"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Adcock Ingram Holdings Limited completes delisting from Johannesburg Stock Exchange and Natco Pharma Limited acquires 35.75% stake",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e5b3491b-bf6c-4d00-8ae4-0eba676b220e.pdf",
            "news_date": "2025-11-12 15:07:06"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Revised Intimation about earnings call for the quarter and half year ended 30th September 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f46ac0e7-5201-49c4-b160-a8bfcaf02545.pdf",
            "news_date": "2025-11-11 12:53:32"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Q2FY26 Un-audited Financial Results Earnings Call",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e28fc1aa-ccb1-414a-b62c-71fc0bcd7757.pdf",
            "news_date": "2025-11-07 12:30:12"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for  Considering  And Approve The Financial Results For The Period Ended September 30 2025 And 2Nd Interim Dividend For The Financial Year Ending 2025-26",
            "news_body": "Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve  the financial results for the period ended September 30 2025 and 2nd Interim dividend for the Financial Year ending 2025-26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ca3187b9-fb80-4e42-b21f-3cd07b59b539.pdf",
            "news_date": "2025-11-07 11:48:14"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "NATCO announces the launch of its Everolimus tablets 1 mg (generic of Zortress)",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cef83faa-be03-425e-9c63-f00105ebb4bd.pdf",
            "news_date": "2025-10-31 09:07:09"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Legal update regarding Risdiplam",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=454cb026-0d5b-468a-b962-11148346f4c9.pdf",
            "news_date": "2025-10-17 17:11:20"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Update on proposed acquisition of Adcock Ingram Holdings Limited",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=353a6fda-842c-483d-bf72-c4c2ac58b00d.pdf",
            "news_date": "2025-10-10 13:09:26"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Compliances - Certificate under Reg 74(5) of SEBI (DP) Regulations for the quarter ended September 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=65cc9695-7c90-4f99-a228-dcf9f6a76692.pdf",
            "news_date": "2025-10-09 18:35:41"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Legal Update regarding RISDIPLAM - commercial  Appellate Division of the Honble Delhi High Court Dismissed Appeal",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=054c4088-e5c2-4a01-9a5a-2e6bb5e2b7f3.pdf",
            "news_date": "2025-10-09 17:36:47"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Management",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
            "news_body": "Mr. G Vijay Kiran Kumar appointed as Vice President - Corporate Quality Assurance (formulations) with effect from 9th October 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=30f7c7d1-98b1-4f74-b885-85721710ea69.pdf",
            "news_date": "2025-10-09 16:45:16"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
            "news_body": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sanjay Nannapaneni",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=94B7F56F_EA9D_49D2_8AFE_45B55DD3C267_095549.pdf",
            "news_date": "2025-10-03 09:56:09"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Management",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
            "news_body": "We would like to inform that De. Santhan Gopalakrishnan Vaidyanathan Senior Vice President - ARD is superannuating from the Company w.e.f. the closure of business hours on 30th September 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=38b1babc-609b-4738-8e4a-4705505a7507.pdf",
            "news_date": "2025-09-30 17:32:26"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Closure of Trading Window",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2e63b350-977e-4d5a-b43d-39d6a993ee30.pdf",
            "news_date": "2025-09-29 16:25:20"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Outcome",
            "descriptor": "AGM",
            "caption": "Shareholder Meeting / Postal Ballot-Scrutinizers Report",
            "news_body": "Scrutinizers Report for the AGM held on 25th September 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fd7f61de-63d5-4dff-bd56-14a45c3ceddc.pdf",
            "news_date": "2025-09-25 18:21:16"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Outcome",
            "descriptor": "AGM",
            "caption": "Shareholder Meeting / Postal Ballot-Outcome of AGM",
            "news_body": "Proceedings of the 42nd Annual General Meeting of the Company",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=64e08b7d-097c-4800-b4d7-214ce3cea193.pdf",
            "news_date": "2025-09-25 12:17:52"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Meeting Updates",
            "caption": "Announcement under Regulation 30 (LODR)-Meeting Updates",
            "news_body": "Outcome of Board Meeting",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=80109949-615b-4e8f-981f-dc75931b30f7.pdf",
            "news_date": "2025-09-25 10:47:00"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
            "news_body": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Satya Vani Nannapaneni",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=473DA5DC_A9D8_46C2_ADC4_E86FE021C285_105254.pdf",
            "news_date": "2025-09-19 10:53:04"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Natcos Pharma Division located in Kothur Hyderabad India has now received Establishment Inspection Report (EIR) classifying the facility as Voluntary Action Indicated (VAI) from the U.S. Food and Drug Administration (FDA)",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3fd96dcf-0af2-4646-a8d1-e3d50cbee17b.pdf",
            "news_date": "2025-09-18 09:49:36"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
            "news_body": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Satya Vani Nannapaneni",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7CF0A56F_2EAC_4B78_AAB2_6FEC5A0505F9_175026.pdf",
            "news_date": "2025-09-15 17:50:30"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Press Release",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ae07e214-287a-4b41-bec3-68a82a4f4a3f.pdf",
            "news_date": "2025-09-10 11:23:04"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of Investor Meet",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=be0711f7-1dfe-437b-a09c-f49d354f3d68.pdf",
            "news_date": "2025-09-04 12:56:07"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "News Paper Publication",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cbb86d3a-b46a-4563-99b3-0cee14785a19.pdf",
            "news_date": "2025-09-01 16:48:41"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Business Responsibility and Sustainability Reporting (BRSR)",
            "caption": "Business Responsibility and Sustainability Reporting (BRSR)",
            "news_body": "Business Responsibility and Sustainability Report for FY 2024-25",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=df85f2c9-9cdc-44c8-af9a-f9ea55e90d23.pdf",
            "news_date": "2025-08-29 18:32:28"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Intimation",
            "descriptor": "AGM",
            "caption": "Notice Of 42Nd Annual General Meeting",
            "news_body": "Notice of 42nd Annual General Meeting",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=92798c05-5abd-43c4-84d7-1591568a76dd.pdf",
            "news_date": "2025-08-29 18:30:36"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Reg. 34 (1) Annual Report",
            "caption": "Reg. 34 (1) Annual Report.",
            "news_body": "Annual Report for Financial Year 2024-25",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=08737473-9fef-496b-881b-746b8ab600b1.pdf",
            "news_date": "2025-08-29 18:10:46"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "NATCO launches Bosentan Tablets for oral suspension (generic of Tracleer) in United States with 180 day exclusivity",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17829baa-e62f-4aac-904e-167f63804619.pdf",
            "news_date": "2025-08-20 10:47:58"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Transcript of Earning call held on 13th August 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7ecea13a-21ca-404b-8fdf-e05856f77026.pdf",
            "news_date": "2025-08-19 17:16:20"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Q1 Earnings Call Audio Link",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1ea0d7fb-cc80-4b11-86e4-7683acfad96b.pdf",
            "news_date": "2025-08-13 15:04:04"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Copy of Newspaper Publication",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dff98f02-fbbd-484a-b3bd-df1253165194.pdf",
            "news_date": "2025-08-13 14:21:23"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Earnings Call Presentation for the quarter ended 30th June 2025",
            "news_id": "954eb01a-a17f-44d5-8cc7-162e0790ae47",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c755548f-c325-46ba-8d7a-8c2108a36a18.pdf",
            "news_date": "2025-08-12 17:38:13",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Earnings Call Presentation for the quarter ended 30th June 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c755548f-c325-46ba-8d7a-8c2108a36a18.pdf",
            "news_date": "2025-08-12 17:38:13"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For The Quarter Ended 30Th June 2025",
            "news_body": "Financial Results for the quarter ended 30th June 2025",
            "news_id": "c358a702-89fd-4f83-b239-282996778fcd",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f60029ee-facd-467a-be0e-d7087b619896.pdf",
            "news_date": "2025-08-12 13:42:42",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Financial Results For The Quarter Ended 30Th June 2025",
            "news_body": "Financial Results for the quarter ended 30th June 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f60029ee-facd-467a-be0e-d7087b619896.pdf",
            "news_date": "2025-08-12 13:42:42"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "Outcome of Board Meeting",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a7e64b53-ebfb-4c2c-b0f5-164f323aeba5.pdf",
            "news_date": "2025-08-12 13:29:22"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Q1FY26 Un-audited Financial Results Earnings Call",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=943f1e46-bc65-4823-b26c-5304b32c6be3.pdf",
            "news_date": "2025-08-06 18:12:22"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Considering The Un-Audited Financial Results For The Quarter Ended 30Th June 2025 And Declaration Of Interim Dividend For The FY25-26",
            "news_body": "Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 inter alia to consider and approve the Un-audited Financial Results for the quarter ended 30th June 2025 and declaration of Interim Dividend for the FY25-26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f454aa80-1645-49ae-9456-c3c09481b0d1.pdf",
            "news_date": "2025-08-04 16:00:07"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Management",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
            "news_body": "Appointment of Mr. T C Mallikarjun as Vice President - Quality Control at Pharma Division Kothur",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ff57567d-ecb8-42a7-b4f3-cb828e5feab1.pdf",
            "news_date": "2025-07-30 16:50:13"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of Investor Call held on 23rd July 2025",
            "news_id": "362956f4-9254-4063-8729-24e910791709",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=26c8d332-fc11-4299-9977-cb8dc43d0153.pdf",
            "news_date": "2025-07-29 16:40:29",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of Investor Call held on 23rd July 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=26c8d332-fc11-4299-9977-cb8dc43d0153.pdf",
            "news_date": "2025-07-29 16:40:29"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "The Company receives Establishment Inspection Report (EIR) from U.S. FDA for the API Unit at Mekaguda",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9a542e80-468f-49ab-a8ae-5728ce11d7e8.pdf",
            "news_date": "2025-07-24 14:03:50"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio Transcript of Investor Call",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0966631b-e380-44b0-b066-b5bda249734d.pdf",
            "news_date": "2025-07-24 10:46:59"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation on Proposed Investment.",
            "news_id": "a9409a6b-022c-439e-9975-3b9265b7aefd",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5c9d7cd0-d102-42c5-89b3-f91787622f9d.pdf",
            "news_date": "2025-07-23 16:36:43",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation on Proposed Investment.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5c9d7cd0-d102-42c5-89b3-f91787622f9d.pdf",
            "news_date": "2025-07-23 16:36:43"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Investor Call on Proposed Investment",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d3f4a2c1-cf35-4323-a38b-3e3aa1272217.pdf",
            "news_date": "2025-07-23 16:28:47"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Acquisition",
            "caption": "Announcement under Regulation 30 (LODR)-Acquisition",
            "news_body": "Outcome of the Board Meeting held on 23rd July 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b64b064e-9935-4c0b-900a-0d7affb236b3.pdf",
            "news_date": "2025-07-23 16:07:51"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Management",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
            "news_body": "Intimation under Reg. 30 for change in designation of Senior Management Personnel of the Company",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5374ccf7-2b5b-48b3-9b29-7ec2fd37e479.pdf",
            "news_date": "2025-07-18 17:50:20"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "News Paper Publication",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a035f914-278a-48fd-a812-acfd92beebc0.pdf",
            "news_date": "2025-07-15 14:37:20"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Certificate under Reg.74(5) of SEBI (DP) Regulations 2018 for the quarter ended June 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2c23ba80-8994-489a-b308-5cb7cdebd151.pdf",
            "news_date": "2025-07-08 15:08:10"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Management",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
            "news_body": "NATCO Pharma Limited would like to inform that the superannuation of Dr. M. Pulla Reddy Executive Vice President - R&D Mr. Ch. Srinivas Senior Vice President - Demand & Supply and resignation of Mr. R. Sridhar Reddy Senior Vice President - GCQA we.f. the closure of business hours on June 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e697b018-cc78-4af6-ae55-eead69a9f865.pdf",
            "news_date": "2025-06-30 17:00:05"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Closure of Trading Window with effect from 1st July 2025 till 48 hours after the declaration of Unaudited Financial Results for the quarter ending June 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fc31343d-6b01-4b0e-89cf-bd7b90d3f5c8.pdf",
            "news_date": "2025-06-26 16:19:48"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015\r\n",
            "news_body": "Update on US FDA Audit at Pharma Division of the Company located at Kothur Hyderabad",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5ff30e17-4720-462e-aa49-154872f4599f.pdf",
            "news_date": "2025-06-19 18:15:24"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Management",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
            "news_body": "Appointment of Mr. Yerramshetty Krishna Rao as Senior Vice President - Operations of the Company w.e.f. 16th June 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a7d2300c-dfdb-4224-8f53-deff6f926d99.pdf",
            "news_date": "2025-06-16 17:51:45"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Press Release On The U.S. Food And Drug Administration (FDA) Inspection At The API Manufacturing Plant Located In Mekaguda Hyderabad",
            "news_body": "Press Release on the U.S. FOOD and Drug Administration (FDA) inspection at the API manufacturing plant located in Mekaguda Hyderabad",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4f0be1f3-2cfb-4161-8f2c-dff082c23394.pdf",
            "news_date": "2025-06-13 16:06:48"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Investor meeting intimation",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5ce4004d-7028-48c5-9032-2ba0df677fb3.pdf",
            "news_date": "2025-06-12 11:38:09"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Q4 FY24-25 Earnings call transcript",
            "news_id": "29117c0c-ae17-4bd6-93ee-09c16149e955",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d43e2593-6819-4d99-b9a6-c3019c901490.pdf",
            "news_date": "2025-06-04 16:28:04",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Q4 FY24-25 Earnings call transcript",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d43e2593-6819-4d99-b9a6-c3019c901490.pdf",
            "news_date": "2025-06-04 16:28:04"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Clarification On Volume Movement",
            "news_body": "Clarification on Volume Movement",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d7087bae-3d61-425a-b09c-08ce2f883916.pdf",
            "news_date": "2025-05-30 12:15:37"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General",
            "descriptor": "Clarification",
            "caption": "Clarification sought from Natco Pharma Ltd",
            "news_body": "The Exchange has sought clarification from Natco Pharma Ltd on May 30 2025 with reference to Movement in Volume.<BR><BR>The reply is awaited.",
            "file_url": "",
            "news_date": "2025-05-30 11:27:47"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Earnings call Recording link",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b267d7b3-4367-4c11-8d76-24cb3db3d83b.pdf",
            "news_date": "2025-05-29 16:42:33"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Copy of Newspaper Publication",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d9f0cd07-78c1-4c68-99b0-f18cebaa8a7f.pdf",
            "news_date": "2025-05-29 13:16:59"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Earnings Presentation for the quarter and year ended 31st March 2025",
            "news_id": "12e1b7d0-a251-4a91-af50-bd1ff1b30355",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aea686c3-f820-4f09-a6a6-99e3468a4042.pdf",
            "news_date": "2025-05-28 18:24:58",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Earnings Presentation for the quarter and year ended 31st March 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aea686c3-f820-4f09-a6a6-99e3468a4042.pdf",
            "news_date": "2025-05-28 18:24:58"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Compliance",
            "descriptor": "Reg.24(A)-Annual Secretarial Compliance",
            "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
            "news_body": "Annual Secretarial Compliance Report for the year ended 31st March 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=db07118f-9724-4de2-bdaf-56608ef4ab0c.pdf",
            "news_date": "2025-05-28 16:03:34"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Management",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
            "news_body": "Intimation under Regulation 30 of SEBI (LODR) Regulations 2015",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=30edb0f8-8036-4b45-8363-8acccf73944a.pdf",
            "news_date": "2025-05-28 15:51:57"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended 31St March 2025",
            "news_body": "Audited Financial Results for the quarter and year ended 31st March 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c8650a03-5d8d-4831-aa6c-28be15bd7dd5.pdf",
            "news_date": "2025-05-28 15:46:17"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Earnings Call with Investors / Analysts at on Thursday the 29th May  2025 at 11:00 AM IST to discuss the Audited Financial Results of the Company for the quarter and year ended 31st March 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9d99c707-0e6c-4740-b8da-229828427c30.pdf",
            "news_date": "2025-05-20 14:16:22"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Audited Financial Results For The Quarter And Year Ended 31St March 2025",
            "news_body": "Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2025 inter alia to consider and approve Audited Financial Results for the quarter and year ended 31st March 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7f0a356c-608e-46df-988f-a0eda0d82039.pdf",
            "news_date": "2025-05-12 16:09:26"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=656b5ae7-7dab-422e-b28f-75b41f343654.pdf",
            "news_date": "2025-04-19 12:25:46"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Compliance",
            "descriptor": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure ",
            "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
            "news_body": "  <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Natco Pharma Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230TG1981PLC003201</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>AA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>ICRA LIMITED</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>NSE</td></tr> </table>  <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: CH VENKAT RAMESH <br/>  Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER <br/> EmailId: venkatramesh.ch@natcopharma.co.in</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: S V V N APPA RAO <br/> Designation: CHIEF FINANCIAL OFFICER <br/> EmailId: svvn@natcopharma.co.in</div> </div> <div> <br/> Date: 09/04/2025<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4f20325b-2970-4e84-86e0-56d0f2fb94f1.pdf",
            "news_date": "2025-04-09 13:11:12"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Legal Update regarding RISDIPLAM launch in India",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=734bcc14-3885-4a1a-be28-21d87e91209c.pdf",
            "news_date": "2025-04-08 11:00:25"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Management",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
            "news_body": "Announcement under Regulation 30 (LODR) Regulations 2015",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fa427aae-b6af-47ea-b18a-2e093e34b7f7.pdf",
            "news_date": "2025-04-03 12:11:45"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Management",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
            "news_body": "Disclosure under regulation 30 of the SEBI (LODR) Regulations 2015",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a3d56186-d1fc-4a9c-990f-caed6379382d.pdf",
            "news_date": "2025-03-31 12:46:03"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Closure of Trading Window",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a784cee9-17cf-4ccd-b8d6-12a65b97b726.pdf",
            "news_date": "2025-03-29 12:11:41"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
            "news_body": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sanjay Nannapaneni",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=CAC00C9A_FCA7_47E2_9F76_C4D3E5906C67_154632.pdf",
            "news_date": "2025-03-27 15:46:41"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
            "news_body": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Rajeev Nannapaneni & Venkata Satya Swathi Kantamani",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1D052F2A_8E63_4C83_982E_7762058350CE_171406.pdf",
            "news_date": "2025-03-21 17:14:29"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011",
            "news_body": "The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Satya Vani Nannapaneni & Sanjay Nannapaneni",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=B2987789_44E8_46E0_973F_51FF713477EE_195412.pdf",
            "news_date": "2025-03-03 19:54:16"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Management",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
            "news_body": "Mr. Bhimrao Dattu Jadhav has been appointed as Senior Vice President - Operations (formulations)  for Pharma Division - Kothur of the Company w.e.f. 3rd March 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5dc3fc3f-2053-4e56-ac68-db1f05383945.pdf",
            "news_date": "2025-03-03 16:39:29"
        },
        {
            "co_code": 4684,
            "bse_code": 524816,
            "isin": "INE987B01026",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Management",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
            "news_body": "Disclosure under Regulation 30of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=55ae1355-aa7c-47d8-9e85-e33d44ec9a74.pdf",
            "news_date": "2025-02-27 18:50:45"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Q3 FY25 Earning Call Transcript",
            "news_id": "2a29dd85-b188-4cd3-85a5-17fba8263bb1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=649d3521-2c1e-4ecd-ab9c-0b1292bb5559.pdf",
            "news_date": "2025-02-19 15:41:06",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Q3 FY25 Earnings Presentation",
            "news_id": "b796dd13-21c6-490b-92bd-89b734b5815e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e7aee70f-0287-4ff8-8d04-253ad95cd48e.pdf",
            "news_date": "2025-02-12 17:08:49",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024",
            "news_body": "Unaudited Financial Results for the quarter and nine months ended December 31 2024",
            "news_id": "9921eb7d-9526-459b-9ddd-bd7190c3e078",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=78c06fa9-fa0e-4350-8f28-6643f3a445b3.pdf",
            "news_date": "2025-02-12 16:03:21",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio recording of earnings conference call Q2 FY25",
            "news_id": "f6e240e5-8237-4f74-a835-09e88383fc7e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=228fbdd9-f03b-4420-b177-3290c1f4e784.pdf",
            "news_date": "2024-11-13 16:49:27",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter and half year ended 30th September, 2024",
            "news_id": "2f476457-f8f3-46bf-b24c-eda15bf9ac35",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=823a6560-df98-4753-b710-06bf7709d994.pdf",
            "news_date": "2024-11-12 17:15:55",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Half Year Ended 30Th September, 2024",
            "news_body": "Unaudited Financial Results for the quarter and half year ended 30th September, 2024",
            "news_id": "3c93d076-c350-4067-bb79-412d77feaafe",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f43a9833-9804-4ef8-8e4d-fe9fa4ae381f.pdf",
            "news_date": "2024-11-12 14:30:05",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings Call Transcript",
            "news_id": "4ed8946f-92c3-4eaf-94a5-7d9e3716ea6b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dba08330-79f4-449b-bfa2-8f5fde18a088.pdf",
            "news_date": "2024-08-21 11:45:37",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings Call Audio Recording weblink",
            "news_id": "2e7c5b66-fcc9-4f34-ab08-df7477207ff0",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=22635544-7f5f-4c0f-86cf-264c562cf1d7.pdf",
            "news_date": "2024-08-13 17:11:59",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter ended 30th June, 2024",
            "news_id": "bbc04c5b-677f-4121-b7e5-082cb4a659cc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4dc8fe95-cdce-4e13-8265-43179359b5cb.pdf",
            "news_date": "2024-08-12 18:38:28",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter Ended 30Th June, 2024",
            "news_body": "Unaudited Financial Results for the quarter ended 30th June, 2024 along with Limited Review Report",
            "news_id": "2e4f89bc-14b5-4ab3-812c-2c6ff6642369",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ed474fc3-2de9-4482-a9fb-7ccec5a48183.pdf",
            "news_date": "2024-08-12 14:00:50",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript for the Earnings call held on 28th May, 2024",
            "news_id": "302a8467-11e6-45ad-9603-da8bb3b73be4",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=99cc0f91-9fd5-4d78-b404-a4e50d143d60.pdf",
            "news_date": "2024-06-04 13:06:00",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation",
            "news_id": "8d0488eb-e159-4af0-bbd6-1c3aafe20828",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=75d97ed4-da5e-4d74-ac80-7744c13a2f59.pdf",
            "news_date": "2024-05-29 19:11:30",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Earnings call Audio Recording",
            "news_id": "64d0dbe4-4d28-46ed-9531-cd99553e5073",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0c34d483-d5ab-48aa-b134-bfd6db34e28d.pdf",
            "news_date": "2024-05-29 11:46:16",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investors Presentation on the Audited Financial Results for the quarter and year ended 31st Match, 2024",
            "news_id": "74d7c9ea-4d1e-45f8-95fb-166765096d26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=92ba56ca-3913-4cf9-8a4e-8ced6baa567d.pdf",
            "news_date": "2024-05-28 10:33:40",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For The Quarter And Year Ended 31St March, 2024",
            "news_body": "Audited Financial Results for the quarter and year ended 31st March, 2024",
            "news_id": "4e5518d4-5135-4311-9f18-d7d809112781",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d20e5ade-c5bb-4e20-ad83-4110f4b838d4.pdf",
            "news_date": "2024-05-27 16:42:36",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Concall Transcript for the quarter and nine months ended December 31, 2023",
            "news_id": "037602c0-fc11-4c7a-af93-b31e705f041a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=98ef9451-83a8-4657-acce-18d31611b872.pdf",
            "news_date": "2024-02-21 16:58:48",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio recording of earnings conference call Q3 FY24",
            "news_id": "c6b0f431-4ff9-4093-a3c1-6cd812da53b8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b128937d-9201-4baa-a3a6-3e8c615bd2ab.pdf",
            "news_date": "2024-02-15 16:48:49",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter and nine months ended December 31, 2023",
            "news_id": "ae8c25dc-c0db-4afc-915f-c0b202919b29",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=66e85b23-3234-404f-986a-92887b4c90dd.pdf",
            "news_date": "2024-02-15 10:16:20",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Nine Months Ended 31St December, 2023",
            "news_body": "Unaudited Financial Results for the quarter and nine months ended 31st December, 2023",
            "news_id": "c42b0c11-e469-447d-83a8-9d47eb732803",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a4c87be9-9d52-4418-8487-470cbb155c89.pdf",
            "news_date": "2024-02-14 14:08:48",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio recording of earnings conference call Q2 FY24",
            "news_id": "bb15938d-f9aa-4695-9075-c5b7c926dfc1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=680ba284-253e-4453-bc47-037b6d722b8a.pdf",
            "news_date": "2023-11-16 11:37:25",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation on Q2FY24 Results",
            "news_id": "885b375e-20b6-4865-87f3-b7050f6a9e74",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8d6d07ff-6eea-4bf3-8b21-89d9b1f3211f.pdf",
            "news_date": "2023-11-15 13:57:03",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For The Quarter And Half Year Ended 30Th September, 2023",
            "news_body": "Financial Results for the quarter and half year ended 30th September, 2023",
            "news_id": "2e2a95ac-f9bd-4c46-859f-34e22ec552a1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ba38ed7d-3f18-422a-9967-8c55f14008a3.pdf",
            "news_date": "2023-11-14 14:14:47",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings call transcript for the quarter ended June 30, 2023",
            "news_id": "6d6f2e26-cacb-4156-b859-835d62d3fa4d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8bcbab47-7dc2-43c5-bf21-1a30b450a20c.pdf",
            "news_date": "2023-08-14 14:11:15",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the Quarter ended 30th June 2023",
            "news_id": "45a654a5-e26b-4d49-ada0-e62697cff46a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a4f2169d-4a45-478e-a28e-fc799b8fc73f.pdf",
            "news_date": "2023-08-10 15:00:51",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Audio recording of Concall Q1FY2024",
            "news_id": "ff54cc9e-2866-491e-a797-5ccb977a601c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7546b2b7-f17e-4ef9-9640-4dc836120f60.pdf",
            "news_date": "2023-08-10 13:04:42",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter Ended 30Th June, 2023",
            "news_body": "Unaudited Financial Results for the quarter ended 30th June, 2023<BR>",
            "news_id": "378b9d54-586b-4fc8-8c20-4e011c9075a8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b83d87c9-b715-4aa0-9aa5-9874b5afe281.pdf",
            "news_date": "2023-08-09 14:50:08",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Q4 FY23 Earnings Call Transcript",
            "news_id": "d9c8aaea-9a68-457b-87f2-e492ce5ffd4e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c09fc44f-6b60-46c9-b248-1d3f3e0244a1.pdf",
            "news_date": "2023-06-01 12:56:21",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter and year ended 31st March, 2023",
            "news_id": "2251a9c5-e031-4a65-89bb-ed779226b938",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=495f5c02-ec86-4da0-87c7-8aa114cac34a.pdf",
            "news_date": "2023-05-30 15:10:20",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings Call Audio recording link",
            "news_id": "c90035bf-805a-4168-9129-0aa0b60a4934",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17fcbdab-740e-40c8-997e-2b4752b6e353.pdf",
            "news_date": "2023-05-30 13:51:07",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results (Standalone And Consolidated) For The Quarter And Year Ended 31St March, 2023",
            "news_body": "Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2023",
            "news_id": "c6ba50ca-0cb5-4958-8ec7-73c51d934c13",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e80bc817-d9b8-44f8-bf70-660996b14349.pdf",
            "news_date": "2023-05-29 14:22:16",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the Company''s earnings conference call for Q3 FY23 held on 10th February, 2023",
            "news_id": "3a7a9b1b-5db6-4468-b700-79f0fb18be52",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6e4b6eb8-33de-4abd-82c2-b060768c6750.pdf",
            "news_date": "2023-02-13 11:48:01",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Audio Transcript of the Earnings call for the Q3 FY23",
            "news_id": "95cafb29-e74b-4c34-9d62-6f8644f6513e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=511a9a76-a53f-41f2-8da4-37ad7af5b7a6.pdf",
            "news_date": "2023-02-10 16:23:40",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter and nine months ended 31st December, 2022",
            "news_id": "bbd7f3f3-8abe-4567-949f-bbb1e004ed5a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2d4c5821-288a-4585-bdd0-08579289e005.pdf",
            "news_date": "2023-02-09 17:40:41",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of The Board Meeting",
            "news_body": "Outcome of the Board Meeting for the un audited financial results for the quarter ended 31st December, 2022",
            "news_id": "8f545982-dc27-4c31-91d1-f5f8d0e42087",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7c257f87-a51e-49b3-83cb-6039dda94271.pdf",
            "news_date": "2023-02-09 14:00:46",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Related Party Transactions For The Half Year Ended 30Th September, 2022",
            "news_body": "Related Party Transactions for the half year ended 30th September, 2022",
            "news_id": "693097f9-7824-4b8e-afaa-48a753f092a1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9e3df443-5edb-4c91-a080-90b4b23ec76e.pdf",
            "news_date": "2022-11-22 16:26:54",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Q2 FY2023 Earnings call Audio Transcript",
            "news_id": "29c0319f-dbb3-4842-8b50-265c68328f98",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9274967b-6fbd-4387-a188-459d24a71eb9.pdf",
            "news_date": "2022-11-11 15:22:30",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the Q2 2023 Financial Results",
            "news_id": "56b8ddb3-46ce-41a7-b004-ae9a7490ad56",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=16dfcdc8-3180-4ff0-931a-d35316b2cb52.pdf",
            "news_date": "2022-11-11 12:52:24",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting",
            "news_body": "Outcome of the Board Meeting held on 10-Nov-2022 to consider the unaudited financial Results for the quarter and half year ended 30th September 2022 and  declared 2nd Interim Dividend of Rs.0.75 (i.e., 37.50%) per Equity shares of Rs.2/- each",
            "news_id": "7be40297-d7b2-4d21-8e6d-75987a39060f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=093fdc5a-f8da-48f4-9148-49696b7ad15b.pdf",
            "news_date": "2022-11-10 13:41:22",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings Call Transcript for the Q1 FY22-23",
            "news_id": "93f853f6-1a54-4846-8d8f-cd36a4931ae4",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=25b58ba7-48ac-4df7-9b6e-c83ac4a01c76.pdf",
            "news_date": "2022-08-17 17:17:20",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "weblink for the Audio Transcript for the  Earnings call  held on 10th August, 2022",
            "news_id": "f4b09abc-ba8b-49b7-8a23-46703136d6b0",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b38c135c-32ae-42bb-bc9f-67b740d71d31.pdf",
            "news_date": "2022-08-10 15:56:29",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter ended 30th June, 2022",
            "news_id": "4c018fd7-60e3-42da-9de1-c956c4119a32",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=68e8f38a-f648-4caf-9a87-5ca041068fc7.pdf",
            "news_date": "2022-08-10 13:18:26",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter Ended 30Th June, 2022 And Interim Dividend",
            "news_body": "Unaudited Financial Results for the Quarter ended 30th June, 2022 and Interim Dividend of Rs.3.50 per equity share of Rs.2/- each",
            "news_id": "2252e38d-53da-4a95-b706-1f30c498a2f5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c41b5d9b-0606-4ddf-8fe9-f034b84bdb95.pdf",
            "news_date": "2022-08-09 14:01:23",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended 30Th June, 2022 And Interim Dividend",
            "news_body": "Unaudited Financial Results for the Quarter ended 30th June, 2022 and Interim Dividend of Rs.3.50 per equity share of Rs.2/- each",
            "news_id": "35675cc9-a529-409b-aad5-dcaa0455981e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=99d5faca-8426-483e-99d8-39c642494faf.pdf",
            "news_date": "2022-08-09 13:58:15",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions For The Half Year Ended 31 March, 2022",
            "news_body": "Disclosure of Related Party Transactions for the half year ended 31 March, 2022",
            "news_id": "b6ec6e48-b56d-4ada-88a2-98948257c091",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c570a312-d2d2-4f00-83d4-18d8de21b193.pdf",
            "news_date": "2022-06-13 16:18:02",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Q4 FY22 Investor Presentation",
            "news_id": "9a4552cb-71d9-48c5-85fb-ae5e6d1f5753",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8ada7c08-5682-4e78-8a85-d6d499d79736.pdf",
            "news_date": "2022-06-07 12:23:45",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Q4 FY 2022 Earnings Call Transcript",
            "news_id": "19a48687-5f64-4480-95ef-4904ce413208",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=59238945-3195-4715-8cff-15f626b21d25.pdf",
            "news_date": "2022-06-04 09:38:19",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Recording of Analysts/Institutional Investor Meet/Con. Call held on 31st May, 2022",
            "news_id": "454d25f0-4c90-4a9e-8ef3-fc0bdc8d8899",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5e14d5b2-6ab8-40d3-9436-393d6532f034.pdf",
            "news_date": "2022-05-31 16:25:38",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For The Quarter And Year Ended 31St March, 2022",
            "news_body": "Financial Results for the quarter and year ended 31st March, 2022",
            "news_id": "42231af8-2d04-435c-afb1-690c22e1bab3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=97a260bf-b5c4-4c67-81cb-2a99176c5e64.pdf",
            "news_date": "2022-05-30 14:54:29",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter and nine months ended 31st December 2021",
            "news_id": "c96ac20b-f298-45fe-b78b-4a8765062667",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7172470b-6a41-49e6-960c-8d7a9de0b5b8.pdf",
            "news_date": "2022-02-17 17:17:20",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "Un audited Financial Results for the Quarter ended 31st December, 2021",
            "news_id": "f2db69b1-0dd3-487f-9ee0-d4e71202935e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=582179e6-49ed-4dd3-a963-843d71d1bbc0.pdf",
            "news_date": "2022-02-14 16:46:11",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter ended September 30, 2021",
            "news_id": "ea7dfccf-45a5-482a-8b4f-692e3f5d7c2d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8dcbceb7-b74f-4ac5-91b3-451a0189a6e8.pdf",
            "news_date": "2021-11-15 11:37:51",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome",
            "news_body": "Unaudited Financial Results for the quarter and half year ended 30th September, 2021<BR>",
            "news_id": "d12a4a3a-b25e-4cc6-b18c-6c03947e0a7b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac96a9b1-c988-4c34-88f7-0fa7bd8f17de.pdf",
            "news_date": "2021-11-11 14:28:36",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter ended June 30, 2021",
            "news_id": "e56a1e8a-ea59-453e-900b-0a74aafae61a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=de0dc8f6-b8ac-4b4c-abff-be5bb4e4b5b0.pdf",
            "news_date": "2021-08-18 12:33:38",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un Audited Financial Results For The Quarter Ended June 30, 2021 Under Regulation 33 Of SEBI (LODR) Regulations, 2015",
            "news_body": "Un Audited Financial Results for the quarter ended June 30, 2021 under Regulation 33 of SEBI (LODR) Regulations, 2015",
            "news_id": "9953c3da-2331-4411-a434-6d2ba0db753d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=22c32dca-0c5d-451f-bf66-8e6344b1fb88.pdf",
            "news_date": "2021-08-12 13:23:00",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Related Party Transaction For The FY 2020-21",
            "news_body": "Related Party Transaction for the FY 2020-21",
            "news_id": "da8e9b97-44e4-4c04-85a0-a5aa63e5bf5d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7ba44c83-a970-42c6-8c9e-f64ecda9d154.pdf",
            "news_date": "2021-07-12 12:34:18",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Q4 Investor presentation for the FY 2020-21",
            "news_id": "3a1931c5-6351-4168-b5fc-a43a7d46f54d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=11064eb4-92a6-4f58-a3ac-2e16a8531a2a.pdf",
            "news_date": "2021-07-12 12:26:59",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For FY 20-21",
            "news_body": "Audited Financial Results for  FY 20-21",
            "news_id": "d88b1e77-1fd5-41f3-9623-58e40fe6f88a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6462e782-c983-4cc0-94bc-9a490f91d990.pdf",
            "news_date": "2021-06-17 15:40:35",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "NATCOPHARM",
            "disp": "Natco Pharma",
            "bse_code": 524816,
            "isin": "INE987B01026",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor presentation for the quarter and nine months ended December 31, 2020",
            "news_id": "fb68626a-a192-41a0-85fd-7a39aa273d5f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8501c6ab-9f8e-4565-8384-fb0126f709a7.pdf",
            "news_date": "2021-02-15 15:25:35",
            "seo": "natco-pharma-ltd",
            "ltp": 850.8,
            "ch": 3.849999999999909,
            "pch": 0.454572288800981,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 3918,
            "exch": "NSE",
            "seg": "E"
        }
    ]
}